Structure Therapeutics Inc. (GPCR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Structure Therapeutics reported revenue of $0. Net income was -$141.2M, or -$0.80 per diluted share. Operating activities generated -$222.2M of cash, leaving -$225.8M of free cash flow. At fiscal year end, Structure Therapeutics held $1.58B in total assets against $67.5M in total liabilities, including $799.6M of cash and equivalents.
Open the full interactive Structure Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Structure Therapeutics Key Stats
| Share Price | $22.31 |
|---|---|
| Market Cap | $1.62B |
| 52-Week Range | $22.31 – $93.79 |
| Shares Outstanding | 218.0 million (basic, 2026 Q2) |
Structure Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$102.8M | -$158.2M | -$176.6M |
| Pre-Tax Income | -$89.4M | -$122.2M | -$140.7M |
| Income Tax | $236,000 | $310,000 | $515,000 |
| Net Income | -$89.6M | -$122.5M | -$141.2M |
| Diluted EPS | -$0.81 | -$0.78 | -$0.80 |
Structure Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$65.7M | $33.0M | -$76.0M | -$106.2M |
| Diluted EPS | -$0.37 | $0.19 | -$0.35 | -$0.49 |
Structure Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $129.8M | $169.5M | $799.6M |
| Current Assets | $473.6M | $891.2M | $1.57B |
| Total Assets | $482.0M | $903.3M | $1.58B |
| Current Liabilities | $24.7M | $36.0M | $63.3M |
| Total Liabilities | $29.1M | $38.5M | $67.5M |
| Shareholders' Equity | $453.0M | $864.8M | $1.52B |
Structure Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$79.5M | -$116.6M | -$222.2M |
| Cash From Investing | -$268.3M | -$358.9M | $89.8M |
| Cash From Financing | $451.5M | $515.3M | $762.5M |
| Free Cash Flow | -$81.7M | -$117.9M | -$225.8M |
Figures from Structure Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Structure Therapeutics financials page for every line item.
Structure Therapeutics Company Profile
| Ticker | GPCR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001888886 |
Frequently Asked Questions
What was Structure Therapeutics' revenue in fiscal 2025?
Structure Therapeutics (GPCR) reported revenue of $0 for fiscal 2025.
What is Structure Therapeutics' annual revenue history?
Structure Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Structure Therapeutics' net income in fiscal 2025?
Structure Therapeutics reported net income of -$141.2M for fiscal 2025.
What was Structure Therapeutics' earnings per share (EPS) in fiscal 2025?
Structure Therapeutics' diluted EPS was -$0.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Structure Therapeutics generate in fiscal 2025?
Structure Therapeutics generated -$225.8M of free cash flow in fiscal 2025.
What was Structure Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Structure Therapeutics reported revenue of $0.
How many shares of Structure Therapeutics are outstanding?
Structure Therapeutics reported a weighted average of 218.0 million basic shares outstanding in 2026 Q2.
What is Structure Therapeutics' market cap?
Based on its latest closing price, Structure Therapeutics (GPCR) has a market capitalization of about $1.62B.
When does Structure Therapeutics' fiscal year end?
Structure Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Structure Therapeutics headquartered?
Structure Therapeutics lists its business address in South San Francisco, California in its SEC filings.